OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform

September 20, 2022

https://www.globenewswire.com/news-release/2022/09/20/2519094/35690/en/OpGen-Subsidiary-Curetis-and-FIND-Sign-R-D-Collaboration-Agreement-for-Unyvero-A30-RQ-Platform.html

ROCKVILLE, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq:OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the signing of an R&D collaboration agreement with FIND, the global alliance for diagnostics, for the Unyvero A30 RQ platform for use in rapid pathogen ID and AMR testing from blood culture samples in low and middle income countries (LMICs).

Read more at globenewswire.com

Related news for (OPGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.